RxDoctor Payments Data

Mubarik Khan, MD

Internal Medicine · Fairfax, VANPI 1336169598

Payments from drug & device makers

$727in general payments, 2019–2025

Across 43 payments — averaging $16.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$269
  • Lilly USA, LLC$162
  • AbbVie$111
  • Johnson & Johnson$49
  • Pfizer$40
  • E.r. Squibb & Sons, L.L.C.$32
  • plus $64 from 3 others

What the payments were for

  • Food & beverage$727100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$727 in reported general payments places this provider in the 70th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$214,294
Medicare patients
360
Services billed
2,716

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide192$215,079
EliquisApixaban78$68,680
JardianceEmpagliflozin55$63,724
JanuviaSitagliptin Phosphate46$51,590
MounjaroTirzepatide34$36,212
JanumetSitagliptin Phos/Metformin Hcl34$33,367
TrulicityDulaglutide26$32,056
XareltoRivaroxaban24$22,363
TradjentaLinagliptin16$22,283
LinzessLinaclotide13$21,803
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$19,633
Tresiba Flextouch U-100Insulin Degludec18$15,652
Breo ElliptaFluticasone/Vilanterol31$13,907
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog26$9,305
GlyxambiEmpagliflozin/Linagliptin12$7,133

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$269$215,079192 claims
Boehringer IngelheimJardiance, Tradjenta, Glyxambi$22$93,13983 claims
PfizerEliquis$40$68,68078 claims
Lilly USA, LLCMounjaro, Trulicity$162$68,26860 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$23$37,95565 claims
AbbVieLinzess, Synthroid$111$23,56339 claims
Johnson & JohnsonXarelto$49$22,36324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Fairfax

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →